Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study.

Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) drive angiogenesis, and several VEGFR inhibitors are already approved for use as single agents or in combination with chemotherapy. Although there is a clear benefit with these drugs in a variety of tumors, the clinical response varies markedly among individuals. Therefore, there is a need for an efficient method to identify patients who are likely to respond to antiangiogenic therapy and to monitor its effects over time. We have recently developed a molecular imaging tracer for imaging VEGFRs known as scVEGF/(99m)Tc; an engineered single-chain (sc) form of VEGF radiolabeled with technetium Tc 99m ((99m)Tc). After intravenous injection, scVEGF/(99m)Tc preferentially binds to and is internalized by VEGFRs expressed within tumor vasculature, providing information on prevalence of functionally active receptors. We now report that VEGFR imaging readily detects the effects of pazopanib, a small-molecule tyrosine kinase inhibitor under clinical development, which selectively targets VEGFR, PDGFR, and c-Kit in mice with HT29 tumor xenografts. Immunohistochemical analysis confirmed that the changes in VEGFR imaging reflect a dramatic pazopanib-induced decrease in the number of VEGFR-2(+)/CD31(+) endothelial cells (ECs) within the tumor vasculature followed by a relative increase in the number of ECs at the tumor edges. We suggest that VEGFR imaging can be used for the identification of patients that are responding to VEGFR-targeted therapies and for guidance in rational design, dosing, and schedules for combination regimens of antiangiogenic treatment.

[1]  R. Kerbel,et al.  Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.

[2]  Ferdia A Gallagher,et al.  A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. , 2009, Neoplasia.

[3]  K. Miller,et al.  Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. , 2009, European urology.

[4]  V. Heinemann,et al.  Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. , 2009, European journal of cancer.

[5]  E. Hayden.  Cutting off cancer's supply lines , 2009, Nature.

[6]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[7]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[8]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[9]  C. Ling,et al.  Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. , 2009, Neoplasia.

[10]  Barry Sloan,et al.  Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. , 2008, Current opinion in investigational drugs.

[11]  Wolfhard Semmler,et al.  Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. , 2008, Cancer research.

[12]  F. Penault-Llorca,et al.  Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. , 2008, European journal of cancer.

[13]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[14]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[15]  Abass Alavi,et al.  Planar and SPECT imaging in the era of PET and PET–CT: can it survive the test of time? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Curzio Rüegg,et al.  Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? , 2008, Nature Clinical Practice Oncology.

[17]  Giuliano Mariani,et al.  Is PET always an advantage versus planar and SPECT imaging? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  F. Blankenberg,et al.  Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. , 2008, Bioconjugate chemistry.

[19]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Mackay,et al.  Targeting the protein kinase C family: are we there yet? , 2008, Nature Reviews Cancer.

[21]  M. Feldman,et al.  Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. , 2008, Biochemical pharmacology.

[22]  Kevin Brindle,et al.  New approaches for imaging tumour responses to treatment , 2008, Nature Reviews Cancer.

[23]  A. Milbourne,et al.  Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers , 2008, Nature Clinical Practice Oncology.

[24]  F. Blankenberg,et al.  Monitoring the Protective Effects of Minocycline Treatment with Radiolabeled Annexin V in an Experimental Model of Focal Cerebral Ischemia , 2007, Journal of Nuclear Medicine.

[25]  R. Kerbel,et al.  Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. , 2007, Cancer research.

[26]  S. Barry,et al.  Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts , 2007, Molecular Cancer Therapeutics.

[27]  Ming-Chih Crouthamel,et al.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity , 2007, Molecular Cancer Therapeutics.

[28]  Zhen-ping Zhu,et al.  VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. , 2007, Experimental cell research.

[29]  Marina V Backer,et al.  Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes , 2007, Nature Medicine.

[30]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[31]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[32]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[33]  Gareth Howell,et al.  Intrinsic Tyrosine Kinase Activity is Required for Vascular Endothelial Growth Factor Receptor 2 Ubiquitination, Sorting and Degradation in Endothelial Cells , 2006, Traffic.

[34]  A. Jubb,et al.  Predicting benefit from anti-angiogenic agents in malignancy , 2006, Nature Reviews Cancer.

[35]  Limor Chen,et al.  Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. , 2006, Cancer research.

[36]  M. Ultsch,et al.  Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.

[37]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[38]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[39]  W. Sessa,et al.  Antiangiogenic therapy: creating a unique "window" of opportunity. , 2004, Cancer cell.

[40]  L. Hutchinson.  Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer? , 2004, Nature Clinical Practice Oncology.

[41]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[42]  Brian H Annex,et al.  A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans , 2002, Clinical pharmacology and therapeutics.

[43]  B. Terman,et al.  Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization , 1999, Oncogene.

[44]  C Gatsonis,et al.  Validation of novel imaging methodologies for use as cancer clinical trial end-points. , 2009, European journal of cancer.

[45]  F. Blankenberg,et al.  Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. , 2008, Methods in molecular biology.

[46]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.